MedTrace Logo

Comparison of Two Dual Therapies in the First-line Treatment of Helicobacter Pylori Infection （SHARE2301）

NCT05870683 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 368

Last updated 2023-07-11

No results posted yet for this study

Summary

Helicobacter pylori (H. pylori) infection is a common global infectious disease of the gastrointestinal tract. Helicobacter pylori eradication can effectively prevent the development of stomach cancer. Progressive application of dual therapy for the eradication of Helicobacter pylori. Tegoprazan, a Potassium-Competitive Acid Blockers. The efficacy of P-CAB agents represented by vonoprazan in H. pylori eradication therapy has been widely verified.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Tegoprazan

Included in dual eradication medication.

DRUG

Amoxicillin

Included in dual eradication medication.

DRUG

Esomeprazole

Included in dual eradication medication.

Sponsors & Collaborators

  • Linyi People's Hospital

    collaborator OTHER

  • Weifang Medical University

    collaborator OTHER

  • Zhengzhou Central Hospital

    collaborator OTHER

  • Yuncheng Traditional Chinese Medicine Hospital

    collaborator OTHER

  • The Affiliated Hospital of Qingdao University

    collaborator OTHER

  • The People's Hospital of Jimo

    collaborator UNKNOWN

  • Shandong University of Traditional Chinese Medicine

    collaborator OTHER

  • Yanqing Li

    lead OTHER

Principal Investigators

  • Yanqing Li · Qilu Hospital of Shandong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-24
Primary Completion
2023-10-01
Completion
2023-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05870683 on ClinicalTrials.gov